L'exposition prénatale aux agonistes β2-adrénergiques et le risque de trouble du spectre de l'autisme chez les descendants

Aperçu: G.M.
L'étude a à examiner le risque de troubles du spectre de l'autisme (TSA) dans la progéniture qui ont été exposés à une utilisation maternelle de l'agoniste β2-adrénergique (β2AA) pendant la grossesse.
Les résultats montrent un risque accru de TSA chez les enfants exposés (IRR = 1.28, 1.11-1.47), en particulier pour ceux qui ont été exposés au cours de la deuxième période (IRR = 1.38, 1.14-1.67). Toutefois, lorsqu'on a prolongé la durée du temps d'exposition à 1 an avant la grossesse, l'étude montre une association similaire chez les enfants nés de femmes qui ont reçu un traitement β2AA pendant la grossesse (IRR = 1.33, 1.11-1.59) à celui des enfants nés chez les femmes qui ont reçu un traitement β2AA, 1 an avant la grossesse
Notre constat a suggéré que les enfants nés de femmes qui ont utilisé β2AA pendant la grossesse ont un risque accru de TSA plus tard, ce qui est plus susceptible d'être dû aux maladies maternelles sous-jacentes que l'exposition à β2AA elle-même.

Pharmacoepidemiol Drug Saf. 2017 Apr 19. doi: 10.1002/pds.4214.

Prenatal exposure to β2-adrenoreceptor agonists and the risk of autism spectrum disorders in offspring

Su X¹, Yuan W², Chen J², Miao M², Olsen J³, Pedersen LH⁴, Liang H², Li J³.

Author information

1

Department of Women and Children's Health Care, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.

2

Key Lab of Reproductive Regulation of NPFPC, SIPPR; IRD, Fudan University, Shanghai, China.

3

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, Denmark.

4

Department of Clinical Medicine, Obstetrics and Gynecology, Aarhus University, Aarhus, Denmark.

Abstract

PURPOSE:

We aimed to examine the risk of autism spectrum disorders (ASDs) in the offspring who were exposed to maternal use of β2-adrenoreceptor agonist (β2AA) during pregnancy.

METHODS:

This is a population-based cohort study including all live singleton births in Denmark from 1 January 1997 to 31 December 2008. Children born to mothers who used β2AA during pregnancy were categorized as exposed, and all other children were included in the unexposed group. Cases of ASDs were identified from the Danish Psychiatric Central Register and the Danish Patient Register. Incidence rate ratio (IRR) and 95% confidence interval were estimated by Poisson regression models.

RESULTS:

Among 751 888 children in the cohort, 9098 (1.21%) received a diagnosis of ASDs. We observed an increased risk of ASDs in the exposed children (IRR = 1.28, 1.11-1.47), especially for those who were exposed during the second trimester period (IRR = 1.38, 1.14-1.67). However, when extending the exposure time window to 1 year prior to pregnancy, we observed a similar association in children born to women who received β2AA treatment during pregnancy (IRR = 1.33, 1.11-1.59) to that in children born to women who received β2AA treatment 1 year prior to pregnancy (IRR = 1.35, 1.17-1.56).

CONCLUSION:

Our finding suggested that children born to women who used β2AA during pregnancy have an increased risk of ASDs in later life, which is more likely due to underlying maternal diseases rather than the exposure to β2AA itself. However, further study, which would better differentiate the effects between indication and medicine, is needed to corroborate the finding. Copyright © 2017 John Wiley & Sons, Ltd.

Copyright © 2017 John Wiley & Sons, Ltd.

PMID: 28422339

DOI: 10.1002/pds.4214